BiotechTube

REGN846

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus, Atopic Dermatitis

Trial Timeline

Jun 1, 2012 → Apr 1, 2013

NCT ID
NCT01605708

About REGN846

REGN846 is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Pruritus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01605708. Target conditions include Pruritus, Atopic Dermatitis.

What happened to similar drugs?

0 of 6 similar drugs in Pruritus were approved

Approved (0) Terminated (1) Active (5)
🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3
🔄Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
❌5 mg Serlopitant TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01605708Phase 1/2Terminated

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
32
SHR0410Jiangsu Hengrui MedicinePhase 1
29
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
25
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
35
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
40
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
35
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
47
BLU-5937 + PlaceboGSK plcPhase 2
35
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
35
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
31
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
32
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
32
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
25
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
19
Serlopitant + PlaceboVyne TherapeuticsPhase 2
17